INmune Bio updates on CORDStrom RDEB timing and XPro Alzheimer's Phase 2 results

Inmune Bio, Inc.

CORDStrom commercial pilot runs completed; MAA to UK MHRA planned mid-2026; BLA to FDA targeted end of 2026.
XPro Phase 2 MINDFuL missed primary endpoint in broad population (n=200) but showed cognitive effect (EMACC d=0.27) in biomarker-defined subpopulation (n=100).
Cash position $27.7M as of Sept 30, 2025, expected to fund operations through year-end 2026.
XPro reduced pTau217 and neuroimaging suggested reduced neurodegeneration in the subgroup.
Regulatory timelines for CORDStrom and XPro remain subject to feedback and manufacturing readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.